PURPOSE: The purpose of this study was to update outcomes of autotransplantation trials for myeloma conducted by the Intergroupe Francophone du Myelome (IFM), the Southwest Oncology Group, and the University of Arkansas for Medical Sciences (Total Therapy [TT]). METHODS: IFM90 (N = 194), IFM04 (N = 402), IFM9902 (N = 692), IFM9904 (N = 197), S9321 (N = 817), TT1 (N = 231), TT2 (N = 668), and TT3 (N = 303) were updated, and results were compared with original reports. RESULTS: Superior survival with single transplantation versus standard therapy in IFM90 was confirmed (P = .004), and a trend in favor of tandem versus single transplantation was maintained in IFM94 (P = .08). S9321 data were validated, with comparable survival in single transplantation and standard treatment arms (P = .35). A survival benefit from thalidomide maintenance in IFM9902 was not confirmed (P = .39) but emerged for the thalidomide arm of TT2 (P = .04). On multivariate analysis, survival was superior in TT2, TT3, and IFM9902 (all P < .001); tandem transplantations were superior to both single transplantations and standard therapies (P < .001), as were tandem transplantations with added thalidomide versus trials without thalidomide (P < .001). Postrelapse survival (PRS) was superior when initial event-free survival (EFS) exceeded 1280 days and when tandem transplantations had been administered, whereas PRS was shorter when EFS lasted 803 days or less and when trials had included thalidomide and bortezomib. CONCLUSION: These long-term follow-up data of transplantation trials provide a crucial framework of reference for outcome reporting of novel agent-based trials reportedly exhibiting remarkable short-term efficacy approaching high-dose therapy results.
PURPOSE: The purpose of this study was to update outcomes of autotransplantation trials for myeloma conducted by the Intergroupe Francophone du Myelome (IFM), the Southwest Oncology Group, and the University of Arkansas for Medical Sciences (Total Therapy [TT]). METHODS: IFM90 (N = 194), IFM04 (N = 402), IFM9902 (N = 692), IFM9904 (N = 197), S9321 (N = 817), TT1 (N = 231), TT2 (N = 668), and TT3 (N = 303) were updated, and results were compared with original reports. RESULTS: Superior survival with single transplantation versus standard therapy in IFM90 was confirmed (P = .004), and a trend in favor of tandem versus single transplantation was maintained in IFM94 (P = .08). S9321 data were validated, with comparable survival in single transplantation and standard treatment arms (P = .35). A survival benefit from thalidomide maintenance in IFM9902 was not confirmed (P = .39) but emerged for the thalidomide arm of TT2 (P = .04). On multivariate analysis, survival was superior in TT2, TT3, and IFM9902 (all P < .001); tandem transplantations were superior to both single transplantations and standard therapies (P < .001), as were tandem transplantations with added thalidomide versus trials without thalidomide (P < .001). Postrelapse survival (PRS) was superior when initial event-free survival (EFS) exceeded 1280 days and when tandem transplantations had been administered, whereas PRS was shorter when EFS lasted 803 days or less and when trials had included thalidomide and bortezomib. CONCLUSION: These long-term follow-up data of transplantation trials provide a crucial framework of reference for outcome reporting of novel agent-based trials reportedly exhibiting remarkable short-term efficacy approaching high-dose therapy results.
Authors: Bart Barlogie; Robert A Kyle; Kenneth C Anderson; Philip R Greipp; Hillard M Lazarus; David D Hurd; Jason McCoy; Dennis F Moore; Shaker R Dakhil; Keith S Lanier; Robert A Chapman; Jeana N Cromer; Sydney E Salmon; Brian Durie; John C Crowley Journal: J Clin Oncol Date: 2006-01-23 Impact factor: 44.544
Authors: Mauricio Pineda-Roman; Maurizio Zangari; Jeff Haessler; Elias Anaissie; Guido Tricot; Frits van Rhee; John Crowley; John D Shaughnessy; Bart Barlogie Journal: Br J Haematol Date: 2008-03 Impact factor: 6.998
Authors: Bart Barlogie; Mauricio Pineda-Roman; Frits van Rhee; Jeff Haessler; Elias Anaissie; Klaus Hollmig; Yazan Alsayed; Sarah Waheed; Nathan Petty; Joshua Epstein; John D Shaughnessy; Guido Tricot; Maurizio Zangari; Jerome Zeldis; Sol Barer; John Crowley Journal: Blood Date: 2008-05-20 Impact factor: 22.113
Authors: Antonio Palumbo; Patrizia Falco; Paolo Corradini; Antonietta Falcone; Francesco Di Raimondo; Nicola Giuliani; Claudia Crippa; Giovannino Ciccone; Paola Omedè; Maria Teresa Ambrosini; Francesca Gay; Sara Bringhen; Pellegrino Musto; Robin Foà; Robert Knight; Jerome B Zeldis; Mario Boccadoro; Maria Teresa Petrucci Journal: J Clin Oncol Date: 2007-09-04 Impact factor: 44.544
Authors: Jesús F San Miguel; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Maria-Victoria Mateos; Kenneth C Anderson; Dixie L Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Paul G Richardson Journal: N Engl J Med Date: 2008-08-28 Impact factor: 91.245
Authors: Roberto J Pessoa de Magalhães; María-Belén Vidriales; Bruno Paiva; Carlos Fernandez-Gimenez; Ramón García-Sanz; Maria-Victoria Mateos; Norma C Gutierrez; Quentin Lecrevisse; Juan F Blanco; Jose Hernández; Natalia de las Heras; Joaquin Martinez-Lopez; Monica Roig; Elaine Sobral Costa; Enrique M Ocio; Martin Perez-Andres; Angelo Maiolino; Marcio Nucci; Javier De La Rubia; Juan-Jose Lahuerta; Jesús F San-Miguel; Alberto Orfao Journal: Haematologica Date: 2012-07-06 Impact factor: 9.941
Authors: Heinz Ludwig; Brian G M Durie; Philip McCarthy; Antonio Palumbo; Jésus San Miguel; Bart Barlogie; Gareth Morgan; Pieter Sonneveld; Andrew Spencer; Kenneth C Andersen; Thierry Facon; Keith A Stewart; Hermann Einsele; Maria-Victoria Mateos; Pierre Wijermans; Anders Waage; Meral Beksac; Paul G Richardson; Cyrille Hulin; Ruben Niesvizky; Henk Lokhorst; Ola Landgren; P Leif Bergsagel; Robert Orlowski; Axel Hinke; Michele Cavo; Michel Attal Journal: Blood Date: 2012-01-23 Impact factor: 22.113
Authors: George Somlo; Ricardo Spielberger; Paul Frankel; Chatchada Karanes; Amrita Krishnan; Pablo Parker; Leslie Popplewell; Firoozeh Sahebi; Neil Kogut; David Snyder; An Liu; Timothy Schultheiss; Stephen Forman; Jeffrey Y C Wong Journal: Clin Cancer Res Date: 2010-11-03 Impact factor: 12.531
Authors: H Ludwig; J S Miguel; M A Dimopoulos; A Palumbo; R Garcia Sanz; R Powles; S Lentzsch; W Ming Chen; J Hou; A Jurczyszyn; K Romeril; R Hajek; E Terpos; K Shimizu; D Joshua; V Hungria; A Rodriguez Morales; D Ben-Yehuda; P Sondergeld; E Zamagni; B Durie Journal: Leukemia Date: 2013-10-09 Impact factor: 11.528